Announcement of the resolution of the third session of the 10th board of directors
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 编号:临2018-004
债券简称:13尖峰01 债券代码:122227
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
十届3次董事会决议公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
一、董事会会议召开情况
(一)本次董事会会议的召集、召开符合有关法律、法规及公司《章程》的相关规定。
(二)2018年4月9日,公司以传真、电子邮件及专人送达的方式发出了本次董事会会议通知。
(三)2018年4月20日,本次董事会会议在浙江省金华市尖峰大厦三楼会议室以现场表决方式召开。
(四)本次董事会会议应出席的董事9人,实际出席会议的董事9人,会议有效表决票数9票。
(五)本次董事会由董事长蒋晓萌主持,公司监事和高级管理人员列席会议。
二、董事会会议审议情况
1、通过了2017年度总经理业务报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
2、通过了2017年度财务决算报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
本报告需提交股东大会审议
3、通过了2017年度利润分配预案
经天健会计师事务所(特殊普通合伙)审计,2017年度公司合并报表归属于母公司股东的净利润为348,494,304.06元;母公司会计报表净利润194,066,681.11元。按母公司的本期净利润194,066,681.11元为基数,提取10%法定公积金19,406,668.11 元,加年初未分配利润570,339,566.43元,减去2016年度现金分红86,020,957.00元,本年度可供分配利润为658,978,622.43元。
公司2017年度拟进行现金分配,以2017年末股本344,083,828股为基数,每10股派发现金红利1.0元(含税),向股权登记日登记在册的全体股东派发现金股利总额为34,408,382.8 元(含税)。
2017年度不进行公积金转增股本。
董事会说明:
(1)现金分红政策执行情况
《公司章程》规定:公司最近三年以现金方式累计分配的利润不少于最近三年实现的年均可分配利润的百分之三十。
从2011年以来,公司连续进行了现金分红,已累计实施现金分红38881.47万元,最近三年现金分红情况如下(2017年度暂按上述预案计算,单位:万元):
|
分红年度 |
现金分红数额 |
当年合并归母公司净利润 |
现金分红占当年合并归母公司净利润比例 |
|
2015年 |
6193.51 |
20089.94 |
30.83% |
|
2016年 |
8602.10 |
28522.95 |
30.16% |
|
2017年 |
3440.84 |
34849.43 |
9.87% |
|
|
最近三年以现金方式累计分配 |
最近三年实现的年均可分配利润 |
最近三年以现金方式累计分配的利润占最近三年实现的年均可分配利润的比例 |
|
|
18236.44 |
27820.77 |
65.55% |
公司最近三年以现金方式累计分配的利润占最近三年实现的年均可分配利润的比例为65.55%,符合公司《公司章程》规定的现金分红政策。
(2)公司的发展情况
目前,公司正处于发展的关键阶段,2018年公司将加快推进上海北卡项目,其子公司安徽新北卡化学有限公司需进行技术改造,建设“年产350吨医药中间体及900吨农药原药项目”;尖峰药业“DPT”项目进入一期临床试验,尖峰药业及其子公司浙江尔婴(原金得尔)、尖峰亦恩将进一步加大产品研发和引进力度;2018年度公司还将继续投入并完成尖峰国贸“新建仓库(电商物流园)项目”;上述业务的开展需要较大的资金支持。
(3)考虑到2018年公司在技改、新产品开发等方面的投入较大,为了保持公司的稳健经营,支持公司的长远发展,兼顾股东的短期和长期利益,董事会通过了上述2017年度利润分配预案。
(4)公司将召开2017年度业绩及现金分红说明会,就公司2017年度业绩及现金分红事项与投资者进行沟通和交流,及时答复投资者关心的问题。
(5)公司在召开股东大会审议上述2017年度利润分配预案时,将为投资者提供网络投票便利条件,同时按照参与表决的A股股东的持股比例分段披露表决结果。
独立董事意见:
(1)同意公司以2017年末股本344,083,828股为基数,每10股派发现金红利1.0元(含税),向股权登记日登记在册的全体股东派发现金股利总额为34,408,382.8元(含税),2017年度不进行公积金转增股本。
(2)该利润分配预案是根据公司2017年度实际经营成果及财务状况,结合公司未来业务发展的实际需要而制定。留存未分配利润主要用于满足公司公司发展的资金需求,有利于公司的持续健康发展,不存在损害股东特别是中小股东权益的情况。我们认为其符合《公司章程》对于利润分配的相关规定,符合公司的实际经营状况。
(3)公司董事会审议通过了上述利润分配预案。我们认为本次会议的召集、召开及审议表决程序符合相关法律、法规及《公司章程》的规定,合法有效;并同意将该预案提交公司2017年年度股东大会审议。
表决结果:同意9票、反对0票、弃权0票。
该预案将提交股东大会审议。
4、通过了聘请公司2018年度审计机构的议案
董事会审议并通过了该议案,同意聘请天健会计师事务所(特殊普通合伙)为公司2018年度财务及内部控制审计机构。
表决结果:同意9票、反对0票、弃权0票。
本议案需提交股东大会审议。
5、通过了2017年年度报告及其摘要
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
本议案需提交股东大会审议。2017年度报告全文及摘要详见上海证券交易所网站(www.sse.com.cn)。
6、通过了关于对控股子公司提供担保的议案
经审议与表决,董事会通过了该议案。
表决结果:同意9票、反对0票、弃权0票。
本议案需提交股东大会审议。
详见《对控股子公司提供担保的公告》(临2018-008)。
7、关于授权董事长利用自有资金进行委托理财的议案
经审议与表决,董事会通过了该议案。
表决结果:同意9票、反对0票、弃权0票。
详见《关于授权董事长利用自有资金进行委托理财的公告》(临2018-007)。
8、关于子公司日常关联交易的议案
董事会审议并通过了该议案。
表决结果:同意7票、反对0票、弃权0票。关联董事蒋晓萌、杜自弘回避了该议案的表决。
详见《关于子公司日常关联交易公告》(临2018-006)。
9、通过了关于召开2017年度股东大会的议案
经审议与表决,董事会通过了该议案。
表决结果:同意9票、反对0票、弃权0票。
详见《关于召开2017年度股东大会的通知》(临2018-010)。
10、通过了2017年度内部控制评价报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
内部控制评价报告详见上海证券交易所网站(www.sse.com.cn)。
11、通过了关于新北卡化学技术改造项目的议案
董事会审议并通过了该议案。同意子公司安徽新北卡化学有限公司投资16274.25万元,其中:固定资产投资为13274.25万元,流动资金3000万元。建设“年产350吨医药中间体及900吨农药原药项目”。
表决结果:同意9票、反对0票、弃权0票。
12、通过了2017年度《中长期激励基金计提方案》
董事会审议并通过了该议案。根据《中长期激励管理办法》的规定,2017年度可提取中长期激励基金为13836266.94元。
表决结果:同意9票、反对0票、弃权0票。
13、通过了董事会审计委员会2017年度履职报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
14、通过了独立董事2017年度述职报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票
独立董事将向股东大会报告。
15、通过了2017年度董事会工作报告
表决结果:同意9票、反对0票、弃权0票。
该报告将提交股东大会审议。
公司独立董事的独立意见:
公司独立董事对上述4、6、7、8、12五项决议发表了独立意见,认为:该决议的形成符合《公司法》、公司《章程》等有关规定,没有损害中小股东的利益。
三、上网公告附件
公司第十届独立董事对上述相关事项的独立董事意见。
特此公告
浙江尖峰集团股份有限公司董事会
二〇一八年四月二十四日
More information
Pharmaceutical Company Established New Drug R & D Promotion Committee
Recently, the new drug research and development promotion committee of Jianfeng pharmaceutical company was formally established, which will be responsible for promoting the new drug research and development progress of pharmaceutical companies and subordinate enterprises, and coordinating the new drug research and development work of various departments and subordinate enterprises. The New Drug Promotion Committee is headed by Huang Jinlong, deputy general manager of the group and general manager of the pharmaceutical company, and Jiang Hong, deputy general manager of the pharmaceutical company, is headed by Pang Xiong, Shi Cunyuan, Xu Lizhen, Yu Jingjing, Zheng Kunwu, Feng Lixiang, Kang Litao, Li Qian, Wu Chonggui, Zhai Tsunami, Huang Fang and Tong Xiaojun. The committee has an office, and Shi Cunyuan is also the director of the office, responsible for the supervision, communication, and coordination of the company's new drug research and development projects. The main responsibilities of the new drug promotion committee include: organizing the establishment and improvement of the R & D project management system and relevant regulations of the pharmaceutical company; organizing the formulation of the development plan of the new drug R & D project of the pharmaceutical company and supervising the implementation; making decisions on project initiation and participating in project evaluation; supervising the management of new drug R & D of the pharmaceutical company and providing guidance; Responsible for the process management of new drug R & D projects and the promotion and coordination of new drug R & D; carry out the assessment of new drug research and development projects; issue the responsibility system assessment and task statement of new drug research and development projects; be responsible for solving major technical problems in the process of new drug research and development; be responsible for the research and improvement of the management mode of research and development projects of pharmaceutical companies; be responsible for the future trend analysis of new drug research and development projects; review the major scientific research achievements of pharmaceutical companies and put forward reward suggestions. Huang Jinlong said that the research and development of new drugs is an important foundation for the healthy development of the pharmaceutical industry and is a systematic project. Jianfeng Pharmaceutical has always attached great importance to the research and development of new drugs, but there is still a certain gap between the progress of research and development and the development process of the enterprise, and the lack of coordination in the research and development process also affects the progress and quality of new drug research and development to a certain extent. The purpose of the establishment of the New Drug Research and Development Promotion Committee is to solve the progress of new drug research and development, to find and solve problems in time, to implement more targeted, and to effectively integrate enterprise resources, improve the speed and quality of new drug research and development, and make good product reserves for the healthy development of pharmaceutical companies. (Reporter Ni Yingzhen)
2020
09-11
Jianfeng Pharmaceutical ranks among the top 100 Chinese pharmaceutical industries in 2019
On August 25, the "2019 Top 100 Series List of China's Pharmaceutical Industry" was released in Kunming. Zhejiang Jianfeng Pharmaceutical Company was shortlisted as one of the top 100 enterprises in China's pharmaceutical industry. The product Berunning (Olopatadine Hydrochloride Eye Drops) was selected as the "Most Growing Product Brand" of China's pharmaceutical industry ". The "Top 100 Pharmaceutical Industry Series List" was evaluated and released by Guangzhou Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, and is known as the "Oscar in Chinese Pharmaceutical Industry. Southern Institute is the earliest institution in China that specializes in pharmaceutical industry policy and market economy research, pharmaceutical market research, pharmaceutical economic data analysis and research, and pharmaceutical professional media publishing. It is in the field of market information value-added services and media communication and marketing services in China's pharmaceutical and health industry., The field of professional quality improvement has extremely extensive influence. The "Top 100 Pharmaceutical Industry" is comprehensively evaluated by the company's annual pharmaceutical industry sales revenue, total profit and R & D investment results. On the same day, the "most growing product brand" of Chinese medicine selected by the Southern Institute's media "Pharmaceutical Economic News" was released simultaneously. Spike Pharmaceuticals product Beirunning (Olopatadine Hydrochloride Eye Drops) was selected. (Xu Yuting)
2020
09-01
Company Disclosure 2020 Semi-Annual Report
On August 28, the Group held the 16th meeting of the 10th Board of Directors of the Company by means of communication, and considered and adopted the "2020 Semi-Annual Report of Jianfeng Group" and the "Proposal on Changes in the Company's Accounting Policy". On August 29, the Company's 2020 semi-annual report was publicly disclosed on the Shanghai Stock Exchange and the Shanghai Securities News and China Securities News. In the first half of the year, the Group focused on the general policy of "grasping projects, making up for shortcomings, improving quality and efficiency, and constantly improving the core competitive advantage", and on the basis of doing a good job in epidemic prevention and control, the Group seized the resumption of work and production, accelerated project construction, and enhanced the core competitiveness of enterprises. In the first half of 2020, the company achieved total operating income of 1.44 billion yuan, net profit attributable to shareholders of 0.368 billion yuan, net profit per share of 1.07 yuan. As of the end of June 2020, the Company's total assets were $5.892 billion, net assets were $4.068 billion, and net assets per share were $11.82. From February to April, affected by the epidemic, the national project construction progress slowed down, cement market demand decreased; after May, the epidemic was effectively controlled, infrastructure investment continued to recover, the real estate industry continued to pick up, cement sales steadily rebounded. During the outbreak, Daye Peak completed the technical transformation projects such as the cold machine, cement mill, into the desulfurization tower anti-corrosion transformation, to ensure the efficient operation of the production equipment after the resumption of work. Yunnan peak rotary kiln production, cement production and other major technical and economic indicators of steady rise; comply with market trends, timely adjustment of marketing policies. Guizhou Jianfeng has promoted the project infrastructure construction, equipment installation and commissioning, raw material bidding and other work in an orderly manner, and through preliminary publicity to enhance the popularity of the Jianfeng brand in the local area, and make a series of preparations for the transformation from project construction to production and operation. In the first half of 2020, the reform of China's medical and health system continued to deepen, and new policies were introduced intensively. Peak Pharmaceuticals and its subsidiaries in the epidemic prevention work at the same time in the first time to achieve the resumption of production, and actively organize donations to support the fight against the epidemic, was named the annual "war epidemic star" the most socially responsible pharmaceutical enterprises. In the first half of the year, Jianfeng Pharmaceutical continued to increase the introduction and development of varieties, and JFAN-1001 applied for clinical application of new anti-tumor drugs. At present, it has obtained the notice of approval for clinical trials. Optimize the production process of API workshop and further shorten the production cycle of raw materials. Continue to improve product sales policies and strengthen market channel control. Shanghai North Carolina further straightened out the internal management structure, production and marketing convergence more smoothly, continue to promote the construction of Anhui North Carolina and Anhui Zhongwang Phase II technical transformation project, promote the peak pharmaceutical raw materials, preparations integration of industrial upgrading strategy. Other business segments of the company actively responded to the challenge of the new crown epidemic and carried out production and operation activities in a standardized and orderly manner. Tianjin natural products company vigorously explore the international and domestic markets, sales revenue to achieve steady growth. Peak Health focuses on the basic idea of "sales orientation, burden reduction and efficiency improvement, fine-grained savings, cost reduction and efficiency enhancement" to effectively improve the operational efficiency of enterprises. Jianfeng International Trade has actively developed new storage business varieties and achieved practical results, and has become the first enterprise in Jinhua to formally obtain the qualification of "network freight. Peak cable seizes the special needs of communication cables such as subways, vigorously promotes large logarithmic cables for subways, and strives to achieve the long tail effect. On the same day, the company also held the 10th meeting of the Ninth Board of Supervisors and reviewed and approved relevant reports. (residual fruit)
2020
09-01
The company organizes new employee induction training
From August 12 to 14, in order to strengthen the training of talents in the group and improve the comprehensive quality of new employees, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, Yu Jianhong, general manager, and other leaders and heads of relevant enterprises and departments conducted a three-day induction training for new employees. New employees from foreign enterprises such as Guizhou Huangping Peak, Daye Peak and Shanghai North Carolina participated simultaneously through online methods. In the course of corporate culture, General Manager Yu Jianhong started from the history of the development and struggle of the peak, divided into five stages: hard work, determined reform, diversified development, strategic adjustment, and strategic development, and introduced in detail the development process of the group company and the current industrial layout., The results achieved; from the aspects of enterprise spirit, vision, development philosophy, values, business philosophy, etc, this paper introduces the peak corporate culture rooted in 62 years of history and inherited in the blood; from the perspective of an enterprise manager and old employees, he speaks a lot of truth to the new employees and puts forward a lot of hopes and suggestions. Chairman Jiang Xiaomeng took "How New Employees Achieve Win-Win with Enterprises" as the topic, and proposed that the key to the success of an enterprise lies in how to select, retain, educate and employ people. Peak and employees complement each other. Peak can achieve today's achievements and the struggle of generations of peak people are inseparable. He also taught new employees the basic concepts that need to be understood, the basic qualities that need to be possessed and the sense of hardship in entering the new environment through 16 key words, and combined with his own experience and quoting from others, he analyzed the core elements of success, the signs of a successful career, the personal qualities that need to be possessed for success, and the importance of establishing a personal knowledge management system, it expresses the ardent hope of new employees to adjust their mentality, keep learning, clear goals, clear dreams, cultivate win-win thinking, and grow up together with the peak. The heads of the human resources department of the group company, the safety management office of the group company, and the comprehensive department of the pharmaceutical company also taught the new employees the corporate rules and regulations and the "Employee Handbook", safety knowledge and professional ethics. The new employees also visited the group exhibition hall and had a deeper understanding of the development history and enterprise achievements of the peak. After the training, the human resources department also organized an examination to test the training effect. (Reporter Chen Shengmu)
2020
08-21
According to this newspaper, through the interconnection monitoring of the transportation department in Zhejiang province, the network freight platform of peak international trading company passed the online service capability audit, interface access audit, eight capability identification and other audit procedures, and successfully obtained the road transportation business license with the qualification of "network freight" on July 2. It is understood that Jianfeng International Trade is currently the first enterprise in Jinhua and Quzhou to obtain this qualification.
2020
08-05
News from our newspaper On July 21, Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State, and Chairman of the Central Military Commission hosted a symposium for entrepreneurs in Beijing and delivered an important speech. Over the past few days, the General Secretary's speech has aroused strong repercussions in all walks of life. On July 23, Jiang Xiaomeng, chairman of the group company, said in an interview with Jinhua TV that the general secretary's speech was calm and inspiring, and pointed out the direction of future work for entrepreneurs.
2020
08-05